"IVF Advisors has been an
astute investor and an understanding partner
with whom we have shared mutual trust and
respect. As investors, they have been open
and fair and we will always value them as
"preferred partners"
-
Ms Kiran Mazumdar - Founder Chairman, Biocon
India Limited.
|
|
Biocon India
Limited, founded by Ms Kiran Mazumdar, is
a pioneering enterprise in the Indian Biotech
Industry. Biocon India manufactures and
markets products in two main segments: therapeutic
bio-molecules for healthcare and specialty
enzymes.
In the healthcare segment, Biocon has combined
its proprietary large-scale manufacturing
technologies with the skill base in synthetic
chemistry at Syngene (a research subsidiary)
to successfully develop bio-molecules for
domestic and overseas pharmaceutical markets.
Biocon's most successful commercialization
has been in the area of "Statins",
which are the largest prescribed anti-cholesterol
drugs in the world. The Company has started
commercial supplies of Lovastatin, Simvastatin,
Pravastatin, and Atorvastatin to world markets.
Biocon's Lovastatin facility had been approved
by USFDA in January 2001. Another drug segment
in which the Company has attained commercial
success is "immunosupressants".
Biocon has successfully scaled up the manufacture
of Mycophenolate Mofetil and Cyclosporin
A, using its proprietary technology.
Biocon is the market leader for industrial
enzymes in India. The Company supplies application-specific
formulations to a diverse range of industry
segments such as brewing, food & beverages,
animal feed, starch processing, textiles,
paper & pulp, detergents, leather, and,
health care. Biocon also exports enzymes
to
|
|
global markets.
Syngene International a fully owned
subsidiary of Biocon India designs and executes
contract research projects for companies in
pharmaceuticals and biotechnology segments.
Syngene has state-of-the-art facilities and
cost competitive, highly skilled, scientific
manpower in the areas of Molecular Biology,
Synthetic Chemistry, and Informatics. Syngene's
access to Biocon's microbial bio-diversity
program, gives it an added advantage in microbial
genomics.
Clinigene International is
a fully owned subsidiary of Biocon India and
conducts longitudinal clinical studies in
select disease segments. The objective is
to create clinical databases to identify new
biomarkers as well as other genotypic and
phenotypic disease indicators. These studies
can result in developing and commercialising
diagnostics and therapies technologies. Clinigene
has the capability to conduct drug-related
bio-studies and pharmacogenomics-based clinical
studies.
IVF exited from its investment in Biocon
when the company listed on the Indian stock
exchange, following its hugely successful
Initial Public Offering in March 2004, which
was subscribed 33 times.
Detailed information on the company available
at www.biocon.com
|
